Dynamic changes and clinical significance of the gut microbiota and serum metabolites in breast cancer onset, progression and chemotherapy intervention - Report - MDSpire
Advertisement
Dynamic changes and clinical significance of the gut microbiota and serum metabolites in breast cancer onset, progression and chemotherapy intervention
Clinical Report: Shifts in Gut Microbiota and Serum Metabolites in Breast Cancer
Overview
This study investigates the dynamic changes in gut microbiota and serum metabolites from benign breast disease to breast cancer and post-chemotherapy. It highlights significant alterations in microbial diversity and metabolomic profiles, suggesting potential biomarkers for disease monitoring.
Background
Understanding the relationship between gut microbiota and breast cancer is crucial as it may influence disease progression and treatment response. The integration of microbiome and metabolomic data could provide insights into the pathophysiology of breast cancer and improve diagnostic and therapeutic strategies.
Data Highlights
Group
Sample Size
Key Findings
BBD
83
Enriched with beneficial bacteria
BC
100
Shift towards inflammation-associated genera
PCBC
88
Accumulation of opportunistic pathogens
Key Findings
The gut microbiota showed significant β diversity changes across BBD, BC, and PCBC groups.
Beneficial bacteria were prevalent in the BBD group, while the BC group exhibited inflammation-associated genera.
Post-chemotherapy, the microbiome further shifted towards pathogenic states.
Over 3,000 metabolites were identified, with significant metabolic disruptions noted in the BC group.
Specific metabolites demonstrated potential as biomarkers with AUC values >0.75 for distinguishing disease stages.
Clinical Implications
The findings suggest that monitoring gut microbiota and serum metabolites could enhance the understanding of breast cancer progression and treatment response. Clinicians may consider these factors when evaluating patient outcomes and tailoring therapeutic approaches.
Conclusion
This study underscores the importance of the gut microbiota and serum metabolome in breast cancer, indicating their potential roles in diagnosis and monitoring treatment responses.
